Stockholders Equity and StockBased Compensation (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 05, 2025 |
Apr. 03, 2025 |
Mar. 14, 2025 |
Mar. 12, 2025 |
Dec. 04, 2024 |
May 23, 2025 |
Mar. 24, 2025 |
Feb. 27, 2025 |
Feb. 26, 2025 |
Nov. 22, 2024 |
Aug. 19, 2024 |
Mar. 29, 2024 |
Feb. 27, 2024 |
Nov. 20, 2023 |
May 28, 2019 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Dec. 31, 2024 |
May 08, 2025 |
|
| Options outstanding, Granted | 10,448 | 58,309 | |||||||||||||||||||
| Exercise price lower range limit | $ 5.74 | $ 1.03 | |||||||||||||||||||
| Total fair value | $ 60,000 | ||||||||||||||||||||
| Stock-based compensation expense | $ 2,106,073 | $ 856,120 | |||||||||||||||||||
| Common Stock, Shares Issued | 25,545,488 | 25,545,488 | 18,783,912 | ||||||||||||||||||
| Unrecognized compensation cost related to option awards | $ 29,155 | $ 29,166 | $ 29,155 | $ 29,166 | |||||||||||||||||
| Unrecognized compensation cost related to option awards vesting period | 1 year 8 months 12 days | 1 year 8 months 12 days | |||||||||||||||||||
| Proceeds from stock option exercise | $ 633,375 | $ 0 | |||||||||||||||||||
| Description of common Stock and Common Stock Equivalents Outstanding | the Company had a total of 25,905,929 shares of common stock and common stock equivalents outstanding, comprised of 25,545,488 common shares outstanding (including outstanding restricted stock awards (RSAs) totaling 1,017,521 shares) and stock options to purchase 360,441 shares of common stock (of which 340,776 stock options were vested). | the Company had a total of 19,248,852 shares of common stock and common stock equivalents outstanding, comprised of 18,783,912 common shares outstanding (including outstanding RSAs totaling 781,864 shares) and stock options to purchase 464,940 shares of common stock (of which 445,275 stock options were vested). | |||||||||||||||||||
| Common Stock, Shares Authorized | 100,000,000 | 100,000,000 | 100,000,000 | ||||||||||||||||||
| ATM Agreement amendment, description | Under this amended agreement, the Company paid Stifel a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the agreement | ||||||||||||||||||||
| Shares of common stock issued | 75,000,000 | 150,000,000.0 | |||||||||||||||||||
| Consulting expense | $ 4,142,501 | $ 2,702,225 | $ 9,288,424 | $ 5,883,793 | |||||||||||||||||
| Weighted average grant date fair value | $ 9.42 | $ 3.00 | |||||||||||||||||||
| Fair value of the Company's common stock per share | $ 13.37 | $ 3.37 | 13.37 | $ 3.37 | |||||||||||||||||
| Fair value of the Company's common stock per share | $ 16.27 | $ 16.27 | $ 16.24 | ||||||||||||||||||
| Offering price, ATM | $ 45,000,000.0 | ||||||||||||||||||||
| Description related to ATM offerings | The Company filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC) on March 29, 2024, registering the sale of up to $75.0 million of the Company’s securities that was declared effective on April 19, 2024. On May 10, 2024, the Company filed a prospectus supplement, which was further supplemented on July 19, 2024 and August 9, 2024 (collectively, the First Prospectus Supplement), pursuant to which the Company offered and sold shares of common stock having an aggregate offering price of up to $12.6 million from time to time through an ATM offering. The Company exhausted all sales under the First Prospectus Supplement | ||||||||||||||||||||
| Series X Preferred Stock [Member] | |||||||||||||||||||||
| Description of subscription and investment representation agreement | (1) share of the Company’s Series X Preferred Stock, par value $0.001 per share (the Series X Preferred Stock), to the Purchaser for $100 in cash. The sale closed on February 27, 2025 and the $100 was received by the Company. The Company redeemed the Series X Preferred Stock for $100 cash after the Annual Meeting and filed the Certificate of Withdrawal with the Secretary of State of Nevada on May 8, 2025 | ||||||||||||||||||||
| Preferred stock voting rights shares | 25,000,000 | ||||||||||||||||||||
| Prepaid Expenses And Other Current Assets [Member] | |||||||||||||||||||||
| Unrecognized compensation cost related to option awards | $ 24,000 | $ 24,000 | |||||||||||||||||||
| Unrecognized compensation cost related to option awards vesting period | 1 month 20 days | ||||||||||||||||||||
| Common Share Issuances [Member] | |||||||||||||||||||||
| Stock-based compensation expense | $ 15,000 | ||||||||||||||||||||
| Shares of common stock issued | 5,181 | 8,750 | |||||||||||||||||||
| Weighted average grant date fair value | $ 5.79 | ||||||||||||||||||||
| 2020 Equity Incentive Plan [Member] | |||||||||||||||||||||
| Total number of common stock available for future issuance | 3,120,331 | 3,120,331 | |||||||||||||||||||
| Description of Equity incentive plan | the Company’s Board of Directors approved an increase of 2,500,000 shares to the authorized number of shares under the 2020 Plan, increasing the total authorized number of shares from 2,500,000 to 5,000,000 | the Board of Directors approved an increase of 700,000 shares to the authorized number of shares under the 2020 Plan, increasing the total authorized number of shares from 1,800,000 shares to 2,500,000 shares | |||||||||||||||||||
| 2025 Transactions [Member] | |||||||||||||||||||||
| Total fair value | $ 300,000 | ||||||||||||||||||||
| Stock-based compensation expense | $ 500,000 | ||||||||||||||||||||
| Shares, vested | 70,710 | ||||||||||||||||||||
| RSAs Modification and Net Share Settlements for Payments of Withholding Taxes, Description | 10,907 RSAs vested to the former employee based on his service to the Company. To satisfy approximately $36,000 in payroll withholding taxes, the Company withheld 3,863 shares, resulting in the issuance of 7,044 net shares to the former employee | approximately $0.2 million in payroll withholding taxes associated with the accelerated RSAs vesting, the Company withheld 21,285 shares, resulting in the issuance of 49,425 net shares to the former employee. The withheld shares were returned to the 2020 Plan share reserve for potential future issuance | |||||||||||||||||||
| RSA Summary 2025 and 2024 [Member] | |||||||||||||||||||||
| Stock-based compensation expense | $ 1,900,000 | $ 800,000 | |||||||||||||||||||
| Common Stock, Shares Issued | 1,017,521 | 1,017,521 | 781,864 | ||||||||||||||||||
| Common Stock, Shares Outstanding | 1,017,521 | 1,017,521 | 781,864 | ||||||||||||||||||
| Fair value of the RSAs vested | $ 500,000 | ||||||||||||||||||||
| Available for sale Securities [Member] | |||||||||||||||||||||
| Stock-based compensation expense | $ 200,000 | $ 300,000 | |||||||||||||||||||
| Proceeds from sale of common stock, shares | 3,636,647 | 400,831 | 6,242,266 | 828,131 | |||||||||||||||||
| Net proceeds from stock issuance under ATM | $ 42,900,000 | $ 1,000,000.0 | $ 63,100,000 | $ 2,200,000 | |||||||||||||||||
| Stock issuence cost | 1,600,000 | $ 100,000 | 2,200,000 | $ 300,000 | |||||||||||||||||
| Options [Member] | |||||||||||||||||||||
| Proceeds from stock option exercise | $ 600,000 | ||||||||||||||||||||
| Proceeds from Stock options, shares | 99,714 | ||||||||||||||||||||
| Board of Directors Chairman [Member] | |||||||||||||||||||||
| Common shares issuances equity grant value | $ 500,000 | $ 180,000 | $ 240,000 | ||||||||||||||||||
| Common shares equity grant price per shares | $ 5.82 | $ 3.97 | |||||||||||||||||||
| Number of shares granted | 85,915 | 60,456 | |||||||||||||||||||
| Compensation cost recognized | $ 180,000 | ||||||||||||||||||||
| Consulting expense | $ 90,000 | ||||||||||||||||||||
| Common stock, valued grant date price per share | $ 2.51 | ||||||||||||||||||||
| Board of Directors Chairman [Member] | Restricted Stock Units R S A [Member] | |||||||||||||||||||||
| Shares, Granted | 28,970 | 57,940 | |||||||||||||||||||
| Restricted stock awards shares | 300,000 | ||||||||||||||||||||
| Stock price per share | $ 6.99 | ||||||||||||||||||||
| Restricted stock awards shares value | $ 2,100,000 | ||||||||||||||||||||
| Weighted average fair value grant date, granted | $ 8.63 | ||||||||||||||||||||
| Unrecognized compensation cost related to option awards | $ 4,900,000 | $ 4,900,000 | |||||||||||||||||||
| Unrecognized compensation cost related to option awards vesting period | 2 years 3 months 14 days | ||||||||||||||||||||
| RSAs vested | 1,000,000.0 | 0 | |||||||||||||||||||
| Fair value of the Company's common stock per share | $ 13.37 | $ 3.37 | $ 13.37 | $ 3.37 | |||||||||||||||||
| Board of Directors [Member] | Maximum | |||||||||||||||||||||
| Common Stock, Shares Authorized | 100,000,000 | ||||||||||||||||||||
| Board of Directors [Member] | Minimum | |||||||||||||||||||||
| Common Stock, Shares Authorized | 25,000,000 | ||||||||||||||||||||